Immunohistochemistry (IHC) showed markedly decreased EGFR expression in the recurrent tumor, post-cetuximab, compared to strong plasma membrane EGFR labeling in the pre-treatment samples (Fig. 2Avs 2B, EGFR). The gene discussed is EGFR; the disease is neoplasm.